Open Label Study of DS-5573a

PHASE1TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Advanced Solid Malignant Tumors
Interventions
DRUG

DS-5573a

"Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1."

Trial Locations (1)

104-0045

National Cancer Center Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY

NCT02192567 - Open Label Study of DS-5573a | Biotech Hunter | Biotech Hunter